{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:45:36Z","timestamp":1794375936162,"version":"4.9.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["12\/35\/64"],"award-info":[{"award-number":["12\/35\/64"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13063-016-1445-7","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T04:24:15Z","timestamp":1469161455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Adjunctive intraocular and peri-ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma (ASCOT): study protocol for a phase III, multi-centre, double-masked randomised controlled trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Philip J.","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria R.","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3634-7845","authenticated-orcid":false,"given":"Rachel","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica W.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon Tudor","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Charteris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,22]]},"reference":[{"issue":"3","key":"1445_CR1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0161-6420(95)31009-3","volume":"102","author":"B Esmaeli","year":"1995","unstructured":"Esmaeli B, Elner SG, Schork MA, Elner VM. Visual outcome and ocular survival after penetrating trauma: a clinicopathologic study. Ophthalmology. 1995;102(3):393\u2013400.","journal-title":"Ophthalmology"},{"issue":"3","key":"1445_CR2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1076\/opep.5.3.143.8364","volume":"5","author":"AD Negrel","year":"1998","unstructured":"Negrel AD, Thylefors B. The global impact of eye injuries. Ophthalmic Epidemiol. 1998;5(3):143\u201369.","journal-title":"Ophthalmic Epidemiol"},{"key":"1445_CR3","first-page":"25","volume-title":"Vision problems in the U.S.: data analysis","author":"National Society to Prevent Blindness","year":"1980","unstructured":"National Society to Prevent Blindness. Vision problems in the U.S.: data analysis. New York: National Society to Prevent Blindness; 1980. p. 25\u20136."},{"issue":"3","key":"1445_CR4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0161-6420(88)33183-0","volume":"95","author":"OD Schein","year":"1988","unstructured":"Schein OD, Hibberd PL, Shingleton BJ, Kunzweiler T, Frambach DA, Seddon JM, et al. The spectrum and burden of ocular injury. Ophthalmology. 1988;95(3):300\u20135.","journal-title":"Ophthalmology"},{"issue":"7","key":"1445_CR5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/bjo.80.7.592","volume":"80","author":"P Desai","year":"1996","unstructured":"Desai P, MacEwen CJ, Baines P, Minassian DC. Incidence of cases of ocular trauma admitted to hospital and incidence of blinding outcome. Br J Ophthalmol. 1996;80(7):592\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"1445_CR6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/09286580701198753","volume":"14","author":"A Pinna","year":"2007","unstructured":"Pinna A, Atzeni G, Patteri P, Salvo M, Zanetti F, Carta F. Epidemiology, visual outcome, and hospitalization costs of open globe injury in northern Sardinia, Italy. Ophthalmic Epidemiol. 2007;14(5):299\u2013305.","journal-title":"Ophthalmic Epidemiol."},{"key":"1445_CR7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2415-8-6","volume":"8","author":"S Cillino","year":"2008","unstructured":"Cillino S, Casuccio A, Di Pace F, Pillitteri F, Cillino G. A five-year retrospective study of the epidemiological characteristics and visual outcomes of patients hospitalized for ocular trauma in a Mediterranean area. BMC Ophthalmol. 2008;8:6.","journal-title":"BMC Ophthalmol."},{"issue":"7","key":"1445_CR8","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0161-6420(97)30167-5","volume":"104","author":"JA Cardillo","year":"1997","unstructured":"Cardillo JA, Stout JT, Labree L, Azen SP, Omphroy L, Cui JZ, et al. Post-traumatic proliferative vitreoretinopathy: the epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology. 1997;104(7):1166\u201373.","journal-title":"Ophthalmology"},{"issue":"4","key":"1445_CR9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-199717040-00001","volume":"17","author":"D Spiegel","year":"1997","unstructured":"Spiegel D, Nasemann J, Nawrocki J, Gabel VP. Severe ocular trauma managed with primary pars plana vitrectomy and silicone oil. Retina. 1997;17(4):275\u201385.","journal-title":"Retina"},{"issue":"5","key":"1445_CR10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-2008-1034716","volume":"215","author":"C Framme","year":"1999","unstructured":"Framme C, Roider J. Epidemiology of open globe injuries [in German]. Klin Monbl Augenheilkd. 1999;215(5):287\u201393.","journal-title":"Klin Monbl Augenheilkd"},{"issue":"3","key":"1445_CR11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0039-6257(99)00104-6","volume":"44","author":"RA Mittra","year":"1999","unstructured":"Mittra RA, Mieler WF. Controversies in the management of open-globe injuries involving the posterior segment. Surv Ophthalmol. 1999;44(3):215\u201325.","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"1445_CR12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.eye.6700194","volume":"16","author":"DG Charteris","year":"2002","unstructured":"Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative vitreoretinopathy\u2014developments in adjunctive treatment and retinal pathology. Eye. 2002;16(4):369\u201374.","journal-title":"Eye"},{"issue":"6","key":"1445_CR13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/00006982-200412000-00007","volume":"24","author":"NN Patel","year":"2004","unstructured":"Patel NN, Bunce C, Asaria RH, Charteris DG. Resources involved in managing retinal detachment complicated by proliferative vitreoretinopathy. Retina. 2004;24(6):883\u20137.","journal-title":"Retina"},{"issue":"10","key":"1445_CR14","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/bjo.79.10.953","volume":"79","author":"DG Charteris","year":"1995","unstructured":"Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995;79(10):953\u201360.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1445_CR15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0161-6420(88)33181-7","volume":"95","author":"RN Johnson","year":"1988","unstructured":"Johnson RN, Blankenship G. A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin. Ophthalmology. 1988;95(3):312\u20137.","journal-title":"Ophthalmology"},{"issue":"6","key":"1445_CR16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0002-9394(14)75196-7","volume":"90","author":"Y Tano","year":"1980","unstructured":"Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90(6):810\u20136.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1445_CR17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00006982-199701000-00009","volume":"17","author":"PE Rubsamen","year":"1997","unstructured":"Rubsamen PE, Cousins SW. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. Retina. 1997;17(1):44\u201350.","journal-title":"Retina"},{"issue":"1","key":"1445_CR18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1167\/iovs.06-0145","volume":"48","author":"TA Albini","year":"2007","unstructured":"Albini TA, Abd-El-Barr MM, Carvounis PE, Iyer MN, Lakhanpal RR, Pennesi ME, et al. Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes. Invest Ophthalmol Vis Sci. 2007;48(1):390\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1445_CR19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF00231411","volume":"219","author":"F Koerner","year":"1982","unstructured":"Koerner F, Merz A, Gloor B, Wagner E. Postoperative retinal fibrosis\u2014a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol. 1982;219(6):268\u201371.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"1445_CR20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/BF00184858","volume":"234","author":"RG Williams","year":"1996","unstructured":"Williams RG, Chang S, Comaratta MR, Simoni G. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol. 1996;234(8):496\u2013503.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"1445_CR21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0008-4182(05)80052-3","volume":"40","author":"WM Munir","year":"2005","unstructured":"Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol. 2005;40(5):598\u2013604.","journal-title":"Can J Ophthalmol"},{"issue":"5","key":"1445_CR22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3928\/15428877-20070901-02","volume":"38","author":"RA Cheema","year":"2007","unstructured":"Cheema RA, Peyman GA, Fang T, Jones A, Lukaris AD, Lim K. Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging. 2007;38(5):365\u201370.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"11","key":"1445_CR23","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ophtha.2008.05.016","volume":"115","author":"H Ahmadieh","year":"2008","unstructured":"Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, Mohebbi MR. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology. 2008;115(11):1938\u201343.","journal-title":"Ophthalmology"},{"issue":"7","key":"1445_CR24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/bjophthalmol-2015-307347","volume":"100","author":"PJ Banerjee","year":"2016","unstructured":"Banerjee PJ, Xing W, Bunce C, Woodcock M, Chandra A, Scott RAH, et al. Triamcinolone during pars plana vitrectomy for open globe trauma: a pilot randomised controlled clinical trial. Br J Ophthalmol. 2016;100(7):949\u201355.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1445_CR25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archophthalmol.2008.610","volume":"127","author":"RW Beck","year":"2009","unstructured":"Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al. Three-year follow-up of a randomized trial comparing focal\/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127(3):245\u201351.","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"1445_CR26","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","volume":"127","author":"IU Scott","year":"2009","unstructured":"Scott IU, Ip MS, Vanveldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115\u201328. A published erratum appears in Arch Ophthalmol. 2009;127(12):1655.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1445_CR27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0886-3350(02)01441-4","volume":"29","author":"MD Conway","year":"2003","unstructured":"Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg. 2003;29(1):27\u201333.","journal-title":"J Cataract Refract Surg"},{"issue":"4","key":"1445_CR28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1442-9071.1998.tb01330.x","volume":"26","author":"JK Challa","year":"1998","unstructured":"Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26(4):277\u201381.","journal-title":"Aust N Z J Ophthalmol"},{"issue":"5","key":"1445_CR29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/00006982-200005000-00024","volume":"20","author":"GA Peyman","year":"2000","unstructured":"Peyman GA, Cheema R, Conway MD, Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina. 2000;20(5):554\u20135.","journal-title":"Retina"},{"issue":"6","key":"1445_CR30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00417-002-0454-2","volume":"240","author":"T Sakamoto","year":"2002","unstructured":"Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol. 2002;240(6):423\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1445_CR31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/IAE.0b013e31816079e8","volume":"28","author":"DV Vasconcelos-Santos","year":"2008","unstructured":"Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina. 2008;28(4):573\u201380.","journal-title":"Retina"},{"key":"1445_CR32","unstructured":"EuroQol Group. EQ-5D-5L user guide. http:\/\/www.euroqol.org\/about-eq-5d\/publications\/user-guide.html . Accessed 9 July 2016."},{"issue":"7","key":"1445_CR33","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"1445_CR34","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ajo.2011.10.013","volume":"153","author":"MT Andreoli","year":"2012","unstructured":"Andreoli MT, Andreoli CM. Surgical rehabilitation of the open globe injury patient. Am J Ophthalmol. 2012;153(5):856\u201360.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"1445_CR35","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.ophtha.2004.05.036","volume":"111","author":"DG Charteris","year":"2004","unstructured":"Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, Bunce C. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004;111(12):2240\u20135.","journal-title":"Ophthalmology"},{"issue":"2","key":"1445_CR36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1517\/14740338.2012.635141","volume":"11","author":"D Veritti","year":"2012","unstructured":"Veritti D, Di Giulio A, Sarao V, Lanzetta P. Drug safety evaluation of intravitreal triamcinolone acetonide. Expert Opin Drug Saf. 2012;11(2):331\u201340.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1445_CR37","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ophtha.2006.08.042","volume":"114","author":"L Wickham","year":"2007","unstructured":"Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007;114(4):698\u2013704.","journal-title":"Ophthalmology"},{"issue":"7","key":"1445_CR38","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0161-6420(01)00589-9","volume":"108","author":"RH Asaria","year":"2001","unstructured":"Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108(7):1179\u201383.","journal-title":"Ophthalmology"},{"key":"1445_CR39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1745-6215-11-32","volume":"11","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32.","journal-title":"Trials."},{"issue":"15","key":"1445_CR40","first-page":"1905","volume":"18","author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E9 Expert Working Group","year":"1999","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E9 Expert Working Group. ICH Harmonized Tripartite Guideline: statistical principles for clinical trials. Stat Med. 1999;18(15):1905\u201342.","journal-title":"Stat Med"},{"issue":"5","key":"1445_CR41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jama.2015.12","volume":"313","author":"JB Holcomb","year":"2015","unstructured":"Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471\u201382.","journal-title":"JAMA"},{"key":"1445_CR42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1745-6215-9-64","volume":"9","author":"RT Edwards","year":"2008","unstructured":"Edwards RT, Hounsome B, Linck P, Russell IT. Economic evaluation alongside pragmatic randomised trials: developing a standard operating procedure for clinical trials units. Trials. 2008;9:64.","journal-title":"Trials."},{"key":"1445_CR43","volume-title":"Economic evaluation in clinical trials","author":"HA Glick","year":"2007","unstructured":"Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2007."},{"key":"1445_CR44","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O\u2019Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.","edition":"3"},{"key":"1445_CR45","volume-title":"Unit costs of health and social care","author":"L Curtis","year":"2014","unstructured":"Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit at the University of Kent; 2014. http:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/2014\/ . Accessed 9 July 2016."},{"key":"1445_CR46","unstructured":"Department of Health. NHS reference costs 2013\u201314 [last updated 9 Mar 2015]. https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2013-to-2014 . Accessed 9 July 2016."},{"key":"1445_CR47","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. https:\/\/www.nice.org.uk\/article\/pmg9\/resources\/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf . Accessed 9 July 2016."},{"issue":"5","key":"1445_CR48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hec.903","volume":"13","author":"E Fenwick","year":"2004","unstructured":"Fenwick E, O\u2019Brien B, Briggs A. Cost-effectiveness acceptability curves \u2013 facts, fallacies and frequently asked questions. Health Econ. 2004;13(5):405\u201315.","journal-title":"Health Econ"},{"issue":"7","key":"1445_CR49","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.88","volume":"313","author":"A Torres","year":"2015","unstructured":"Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313(7):677\u201386.","journal-title":"JAMA"},{"issue":"9460","key":"1445_CR50","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(05)70939-9","volume":"365","author":"DAMOCLES Study Group","year":"2005","unstructured":"DAMOCLES Study Group. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365(9460):711\u201322.","journal-title":"Lancet."},{"key":"1445_CR51","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Expert Working Group. ICH Harmonised Tripartite Guideline for Good Clinical Practice E6(R1). 1996. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf . Accessed 9 July 2016."},{"key":"1445_CR52","unstructured":"European Union. Directive 2001\/20\/EC of the European Parliament and of the Council. 2001. http:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32001L0020&qid=1468070960730&from=EN . Accessed 9 July 2016."},{"key":"1445_CR53","unstructured":"The Medicines for Human Use (Clinical Trials) Regulations 2004. http:\/\/www.legislation.gov.uk\/uksi\/2004\/1031\/contents\/made . Accessed 9 July 2016."},{"issue":"20","key":"1445_CR54","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA."},{"issue":"3","key":"1445_CR55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-016-1445-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T11:15:31Z","timestamp":1718709331000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-016-1445-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,22]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1186\/s13063-016-1445-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,22]]},"article-number":"339"}}